Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00248313 | Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus | PHASE3 | COMPLETED | 470 | — | — | Jul 1, 2000 | Oct 1, 2007 | Mar 10, 2010 | - | — |
| Name | Type | Description |
|---|---|---|
| Rapamune® | DRUG | - |
Inclusion Criteria: * Age: = to ≥ 18 years. * End-stage renal disease, with patients scheduled to receive a primary or secondary renal allograft from a cadaveric donor, from a living-unrelated donor, or from a living-related donor. * Patients with second and subsequent transplants must have maintai...